Key facts
- Acclinate’s last known valuation is $40.0M (May 2024).
- It has raised $15.6M across 3 recorded rounds; the latest was Seed Round ($3.5M) in Feb 2026.
- Notable investors include Techstars, Google for Startups, Gaingels, gener8tor, Realm Capital Ventures — 24 tracked in total.
- Acclinate has filed 3 Form Ds with the SEC since 2022, most recently Apr 2026 ($3.5M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Acclinate
Funding rounds
3 roundsAbout Acclinate
Developer of a digital health platform designed to facilitate an increase in representation and diversity of their genomic research and clinical trials. The company's platform utilizes machine learning and predictive analytics to automate the identification, education, engagement, and retention of willing and diverse genomic research and clinical trial participants, enabling biopharmaceutical research organizations to decrease the overall cost of drug development.
- Sector
- Healthcare
- HQ
- Birmingham, AL, United States
- Founded
- 2020
- Employees
- 62
- Website
- acclinate.com/
- Ownership
- Privately Held (backing)
Acclinate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acclinate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acclinate in its N-PORT filings yet. We sweep new filings monthly.